Skip to main content
. 2021 Nov;17(11 Suppl 6):17–18.

Figure 5.

Figure 5.

Median progression-free survival according to the NLR in a retrospective, multicenter analysis of patients with advanced hepatocellular carcinoma treated with first-line atezolizumab plus bevacizumab. NLR, neutrophil-to-lymphocyte ratio. Adapted from Cheon J et al. ESMO abstract 955P. Ann Oncol. 2021;32(suppl 5).2